Merck Likes Biosimilars, But Not ESAs

Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements